Stock NBIO NASCENT BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Market Closed - OTC Markets
Other stock markets
 15:50:47 2024-05-31 EDT 		5-day change 1st Jan Change
0.099 USD +0.51% Intraday chart for Nascent Biotech, Inc. +1.43% -42.74%
04-16 Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run CI
03-19 Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
AQ
Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
CI
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab
CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
CI
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is significantly under Valued
AQ
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
AQ
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt
CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement
CI
Nascent Biotech : Termination of Material Agreement - Form 8-K
PU
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials
CI
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)
AQ
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIO Stock
  4. News Nascent Biotech, Inc.